AbstractObjectivesTo compare the pharmacodynamic effects of clopidogrel reloading vs. switching to prasugrel or ticagrelor in high on treatment platelet reactivity (HTPR) patients undergoing percutaneous coronary intervention (PCI).MethodsProspective, single-centre study wherein consecutive patients undergoing nonemergent PCI showing HTPR on 600mg clopidogrel loading were randomized to either clopidogrel reloading (300mg load, 75mg OD) or prasugrel (60mg load, 10mg OD-in patients>60kg) or ticagrelor (180mg load, 90mg BD). HTPR is defined as maximum platelet aggregation (MPA)>46% assessed by 5μmol/L adenosine diphosphate light transmission aggregometry (ADP-LTA) assay after more than 6h of clopidogrel loading. Platelet function were assessed...
High on-treatment platelet reactivity (HPR) has been identified as an independent risk factor for is...
Abstract Background: In patients undergoing primary percutaneous coronary intervention (PPCI) ticagr...
BACKGROUND: The increasing use of higher-than-approved doses of clopidogrel in clinical practice is ...
Objectives: To compare the pharmacodynamic effects of clopidogrel reloading vs. switching to prasugr...
AbstractObjectivesTo compare the pharmacodynamic effects of clopidogrel reloading vs. switching to p...
Abstract Background Patients with reduced responsiveness to clopidogrel often have diminished platel...
ObjectivesThe study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute c...
Background Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute co...
Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary synd...
Aims: Repeated loading doses (LD) of clopidogrel were shown to effectively overcome high-on-clopidog...
In patients undergoing primary percutaneous coronary intervention (PPCI) ticagrelor is superior to c...
Background: Adding a prasugrel loading dose (LD) to a clopidogrel LD could be desirable because clop...
background: Repeated loading doses (LD) of clopidogrel were shown to effectively overcome high on-cl...
Objectives The objective was to evaluate the pharmacodynamic response of switching patients on maint...
The prevalence of high platelet reactivity (HPR) in patients who have switched from clopidogrel to p...
High on-treatment platelet reactivity (HPR) has been identified as an independent risk factor for is...
Abstract Background: In patients undergoing primary percutaneous coronary intervention (PPCI) ticagr...
BACKGROUND: The increasing use of higher-than-approved doses of clopidogrel in clinical practice is ...
Objectives: To compare the pharmacodynamic effects of clopidogrel reloading vs. switching to prasugr...
AbstractObjectivesTo compare the pharmacodynamic effects of clopidogrel reloading vs. switching to p...
Abstract Background Patients with reduced responsiveness to clopidogrel often have diminished platel...
ObjectivesThe study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute c...
Background Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute co...
Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary synd...
Aims: Repeated loading doses (LD) of clopidogrel were shown to effectively overcome high-on-clopidog...
In patients undergoing primary percutaneous coronary intervention (PPCI) ticagrelor is superior to c...
Background: Adding a prasugrel loading dose (LD) to a clopidogrel LD could be desirable because clop...
background: Repeated loading doses (LD) of clopidogrel were shown to effectively overcome high on-cl...
Objectives The objective was to evaluate the pharmacodynamic response of switching patients on maint...
The prevalence of high platelet reactivity (HPR) in patients who have switched from clopidogrel to p...
High on-treatment platelet reactivity (HPR) has been identified as an independent risk factor for is...
Abstract Background: In patients undergoing primary percutaneous coronary intervention (PPCI) ticagr...
BACKGROUND: The increasing use of higher-than-approved doses of clopidogrel in clinical practice is ...